

J.V. Melo · J.M. Goldman

Hematologic Malignancies: Myeloproliferative Disorders

J.V. Melo · J.M. Goldman

Hematologic Malignancies: Myeloproliferative Disorders

With 69 Figures and 52 Tables

Junia V. Melo
Department of Haematology
Faculty of Medicine
Imperial College London
Hammersmith Hospital
Du Cane Road
London W12 0NN
UK

John M. Goldman
Hematology Branch
National Heart, Lung and Blood Institute
National Institutes of Health
Bethesda, MD 20892
USA

ISBN-10 3-540-34505-1 Springer Berlin Heidelberg New York
ISBN-13 978-3-540-34505-3 Springer Berlin Heidelberg New York

Library of Congress Control Number: 2006926428

A catalog record for this book is available from Library of Congress.

Bibliographic information published by Die Deutsche Bibliothek.
Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie;
detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer is a part of Springer Science+Business Media
springer.com

© Springer Berlin Heidelberg 2007

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about the application of operative techniques and medications contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Editor: Dr. Ute Heilmann, Heidelberg, Germany
Desk editor: Meike Stoeck, Heidelberg, Germany
Production: LE-TeX Jelonek, Schmidt & Vöckler GbR, Leipzig, Germany
Typesetting: K + V Fotosatz GmbH, Beerfelden, Germany
Cover design: Erich Kirchner, Heidelberg, Germany

21/3100/YL - 5 4 3 2 1 0 - Printed on acid-free paper

Preface

“... To put together such apparently dissimilar diseases as chronic granulocytic leukemia, polycythemia, myeloid metaplasia and diGuglielmos's syndrome may conceivably be without foundation, but for the moment at least, this may prove useful and even productive. What more can one ask of a theory?”

So ended the editorial entitled “Some Speculations on the Myeloproliferative Syndromes” published in *Blood* in 1951 by the journal editor, William Dameshek. He speculated that these various conditions, which he had termed “myeloproliferative,” were all somewhat variable manifestations of proliferative activity of the bone marrow cells, perhaps due to “a hitherto undiscovered stimulus.” More than half a century later, Dameshek would probably have been pleased to learn that much has been learned about the cellular defects that cause these various disorders and that the term he coined has survived more or less intact. True, research focuses today as much on genetic abnormalities intrinsic in the clonal populations as on the dysregulation of cytokines or other stimulatory factors that contribute to features of these different diseases. However, in general his grouping of seemingly disparate diseases has stood the test of time. Chronic granulocytic leukemia has been renamed chronic myeloid leukemia or chronic myelogenous leukemia, and myeloid metaplasia is now idiopathic myelofibrosis – semantics only. On the other hand, erythroleukemia (diGuglielmos's syndrome) is now more usually classified as a form of acute leukemia, and the remaining myeloproliferative disorders are often referred to as the *chronic* myeloproliferative disorders, perhaps to distinguish them from the acute myeloid leukemias. One problem remains: Is chronic myeloid leukemia correctly included in this category of disease? For the purposes of this book we have elected to say that it is, though others might disagree.

We believe that recent advances in understanding the molecular and cellular biology of these disorders, taken in conjunction with the remarkable progress in treatment makes, this book especially timely. It would not be appropriate to attempt to summarize here all these advances, but clearly the gradual unraveling of the molecular basis of CML which led to the development and eventual clinical use of imatinib, all documented by various authors in this book, will come to be recognized as one of the great landmarks in the history of malignant disease. Many hope, not without good reason, that it may prove to be the model on which progress in understanding and treating other malignant hematological disorders and indeed solid tumors can be based. The major redirection of research efforts, both academic and pharmaceutical, bears eloquent testimony to this not unreasonable belief.

We do not regard this book as targeted to any particular audience. We believe it should be of interest to medical students who find the specialty of hematology truly fascinating, as we ourselves did some years ago and still do. We hope it will also attract the interest of established basic researchers and accredited hematologists, because we have stressed to our authors the need to up-date their stories to 2006, and this they have done. To many people who are no longer students but not yet established clinicians or scientists, this book should also appeal and, hopefully, be an inspiration for joining the

teams of doctors and scientists who strive to understand the origins of the myeloproliferative disorders and to exploit the opportunities for improving therapy still further.

Finally, we are especially grateful to our authors who contributed excellent chapters – mostly on time – and who serenely accepted our detailed requests in some cases for further expansion or clarification of their manuscripts. We thank also our publishers for what in the end turned out to be an amazingly painless transition from manuscript to book.

London, July 2006

Junia V. Melo
John M. Goldman

Table of Contents

1	Chronic Myeloid Leukemia – A Brief History	1	11	Immune Therapy of Chronic Myelogenous Leukemia	185
	<i>John M. Goldman, George Q. Daley</i>			<i>Axel Hoos, Robert P. Gale</i>	
2	Bcr-Abl and Signal Transduction	15	12	Therapeutic Strategies and Concepts of Cure in CML . .	201
	<i>Daniela Cilloni, Giuseppe Saglio</i>			<i>Tariq I. Mughal, John M. Goldman</i>	
3	Chronic Myeloid Leukemia: Biology of Advanced Phase . . .	37	13	BCR-ABL-Negative Chronic Myeloid Leukemia	219
	<i>Junia V. Melo, David J. Barnes</i>			<i>Nicholas C.P. Cross, Andreas Reiter</i>	
4	Clinical Features of CML	59	14	Hypereosinophilic Syndrome . .	235
	<i>Patricia Shepherd, Mira Farquharson</i>			<i>Elizabeth H. Stover, Jason Gotlib, Jan Cools, D. Gary Gilliland</i>	
5	Signal Transduction Inhibitors in Chronic Myeloid Leukemia . .	75	15	Chronic Idiopathic Myelofibrosis	253
	<i>Michael W.N. Deininger</i>			<i>John T. Reilly</i>	
6	Treatment with Tyrosine Kinase Inhibitors	109	16	Polycythemia Vera – Clinical Aspects	277
	<i>Andreas Hochhaus</i>			<i>Alison R. Moliterno, Jerry L. Spivak</i>	
7	Allogeneic Transplantation for CML	115	17	Polycythemia Vera and Other Polycythemic Disorders – Biological Aspects	297
	<i>Charles Crawley, Jerald Radich, Jane Apperley</i>			<i>Sonny O. Ang, Josef T. Prchal</i>	
8	Autografting in Chronic Myeloid Leukemia	133	18	Essential Thrombocythemia . . .	321
	<i>Eduardo Olavarria</i>			<i>Ayalew Tefferi</i>	
9	Monitoring Disease Response . .	143		Subject Index	349
	<i>Timothy Hughes, Susan Branford</i>				
10	New Therapies for Chronic Myeloid Leukemia	165			
	<i>Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes</i>				

Contributors

SONNY O. ANG
St Jude Children's Research Hospital
332 N. Lauderdale St.
Memphis, TN 38103, USA

JANE APPERLEY
Department of Haematology
Faculty of Medicine
Imperial College London
Hammersmith Hospital
Du Cane Road
London W12 0NN, UK

DAVID J. BARNES
Department of Haematology
Faculty of Medicine
Imperial College London
Hammersmith Hospital
Du Cane Road
London W12 0NN, UK

SUSAN BRANFORD
Institute of Medical and Veterinary Science
University of Adelaide, North Terrace
Frome Road
Adelaide, 5000 SA, Australia

DANIELA CILLONI
Department of Clinical and Biological Sciences
of the University of Turin
San Luigi Hospital, Gonzole 10
10043 Orbassano-Torino, Italy

JAN COOLS
Department of Human Genetics
University of Leuven
Leuven, Belgium

JORGE CORTES
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
1515 Holcombe Boulevard, Unit 428
Houston, TX 77030, USA

CHARLES CRAWLEY
Department of Haematology
Addenbrooke's Hospital
Hills Road
Cambridge CB2 2QQ, UK

NICHOLAS C. P. CROSS
Wessex Regional Genetics Laboratory
Salisbury District Hospital
Salisbury SP2 8BJ, UK

GEORGE Q. DALEY
Division of Hematology/Oncology
Children's Hospital
300 Longwood Ave.
Boston, MA 02115, USA

MICHAEL W.N. DEININGER
Oregon Health & Science University
Center for Hematologic Malignancies
3181 SW Sam Jackson Park Road
Portland, OR 97239, USA

MIRA FARQUHARSON
Specialist Registrar in Haematology
Western General Hospital
Edinburgh EH4 2XU, Scotland

ROBERT P. GALE
Ziopharm, Inc.
11693 San Vicente Boulevard, Suite 335
Los Angeles, CA 90049-5105, USA

D. GARY GILLILAND
Howard Hughes Medical Institute
Harvard Medical School
Karp Family Research Laboratories
1 Blackfan Circle, Room 5210
Boston, MA 02115, USA

JOHN M. GOLDMAN
Hematology Branch
National Heart, Lung and Blood Institute
National Institutes of Health
Bethesda, MD 20892, USA

JASON GOTLIB
Stanford University School of Medicine
Stanford, CA, 94305, USA

ANDREAS HOCHHAUS
III. Medizinische Klinik
Fakultät für Klinische Medizin Mannheim
der Universität Heidelberg
Theodor-Kutzer-Ufer 1-3
68167 Mannheim, Germany

AXEL HOOS
Bristol-Myers Squibb
5 Research Parkway
Wallingford, CT 06492, USA

TIMOTHY HUGHES
Institute of Medical and Veterinary Science
University of Adelaide, North Terrace
Frome Road
Adelaide, 5000 SA, Australia

HAGOP KANTARJIAN
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
1515 Holcombe Boulevard, Unit 428
Houston, TX 77030, USA

JUNIA V. MELO
Department of Haematology
Faculty of Medicine
Imperial College London
Hammersmith Hospital
Du Cane Road
London W12 0NN, UK

ALISON R. MOLITERNO
Johns Hopkins University School of Medicine
Ross Research 1025
720 Rutland Ave
Baltimore, MD 21205, USA

TARIQ I. MUGHAL
Division of Hematology
and Stem Cell Transplantation
University of Texas
Southwestern School of Medicine
Dallas, TX 75390, USA

EDUARDO OLAVARRIA
Consultant Haematologist
Catherine Lewis Centre
Haematology Department
Hammersmith Hospital
Du Cane Road
London W12 0NN, UK

JOSEF T. PRCHAL
University of Utah
Hematology Division
30 N. 1900 East, 4C416 SOM
Salt Lake City, UT 84132-2408, USA

ALFONSO QUINTÁS-CARDAMA
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
1515 Holcombe Boulevard, Unit 428
Houston, TX 77030, USA

JERALD RADICH
Clinical Research Division
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N.
Seattle, WA 98109, USA

JOHN T. REILLY
Consultant Haematologist
Royal Hallamshire Hospital
Glossop Road
Sheffield S10 2JF, UK

ANDREAS REITER
Medizinische Universitätsklinik
Fakultät für Klinische Medizin Mannheim
der Universität Heidelberg
68167 Mannheim, Germany

GIUSEPPE SAGLIO
Department of Clinical and Biological Sciences
of the University of Turin
San Luigi Hospital, Gonzole 10
10043 Orbassano-Torino, Italy

PATRICIA C. SHEPHERD
Consultant Haematologist
Western General Hospital
Edinburgh EH4 2XU, Scotland

JERRY L. SPIVAK
Johns Hopkins University School of Medicine
Traylor 924
720 Rutland Ave
Baltimore, MD 21205, USA

ELIZABETH H. STOVER
Division of Hematology
Department of Medicine
Brigham and Women's Hospital
Harvard Medical School
and the Howard Hughes Medical Institute
Boston, MA 02115, USA

AYALEW TEFFERI
Division of Hematology
Mayo Clinic
200 First St. SW
Rochester, MN 55905, USA